Patients with a CR or PR at the 1-year landmark and no secondary systemic treatment before the 1-year landmark have a shorter time to end of systemic treatment and better subsequent survival than do those with stable disease or progression at the landmark or secondary systemic treatment before the landmark. (A) Cumulative incidence of ended systemic treatment. (B) Survival after the 1-year landmark. CR/PR indicates complete or partial response at the time of assessment (n = 39). SD/PD indicates stable or progressive disease at the time of assessment (n = 59). New Rx indicates patients who received secondary systemic treatment of chronic GVHD before the landmark (n = 104). A few patients ended systemic treatment before the landmark. IST, immunosuppressive treatment.